Repositioning Candidate Details
| Candidate ID: | R1595 |
| Source ID: | DB16398 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Efmarodocokin alfa |
| Synonyms: | Efmarodocokin alfa; IL 22-FC; IL-22Fc |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia). |
| CAS Number: | 1953227-87-6 |
| Molecular Weight: | |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Efmarodocokin alfa is a human IL-22Fc IgG4 fusion protein that activates the IL-22 pathway being investigated for inflammatory diseases. Studies show activation of STAT3 in primary human hepatocytes and human colon cell lines. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |